Skip to main content
Erschienen in: Diabetologia 9/2019

Open Access 18.07.2019 | Article

Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals

verfasst von: Toshiaki Ohkuma, Yuji Komorita, Sanne A. E. Peters, Mark Woodward

Erschienen in: Diabetologia | Ausgabe 9/2019

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Aims/hypothesis

The prevalence of diabetes and heart failure is increasing, and diabetes has been associated with an increased risk of heart failure. However, whether diabetes confers the same excess risk of heart failure in women and men is unknown. The aim of this study was to conduct a comprehensive systematic review with meta-analysis of possible sex differences in the excess risk of heart failure consequent to diabetes. Our null hypothesis was that there is no such sex difference.

Methods

A systematic search was conducted in PubMed for population-based cohort studies published between January 1966 and November 2018. Studies were selected if they reported sex-specific estimates of RRs for heart failure associated with diabetes, and its associated variability, which were adjusted at least for age. Random-effects meta-analyses with inverse variance weighting were used to obtain pooled sex-specific RRs and women-to-men ratio of RRs (RRRs) for heart failure associated with diabetes.

Results

Data from 47 cohorts, involving 12,142,998 individuals and 253,260 heart failure events, were included. The pooled multiple-adjusted RR for heart failure associated with type 1 diabetes was 5.15 (95% CI 3.43, 7.74) in women and 3.47 (2.57, 4.69) in men, leading to an RRR of 1.47 (1.44, 1.90). Corresponding pooled RRs for heart failure associated with type 2 diabetes were 1.95 (1.70, 2.22) in women and 1.74 (1.55, 1.95) in men, with a pooled RRR of 1.09 (1.05, 1.13).

Conclusions/interpretation

The excess risk of heart failure associated with diabetes is significantly greater in women with diabetes than in men with diabetes.
PROSPERO registration: CRD42019135246
Begleitmaterial
Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s00125-019-4926-x) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
RRR
Ratio of RR

Introduction

Diabetes and heart failure are now recognised as frequent comorbid conditions; the prevalence of type 2 diabetes in individuals with heart failure was reported to be 4.3–28%, whilst that of heart failure in those with type 2 diabetes was reported to be 12–57% [1]. Diabetes is associated with an increased risk of heart failure [2], and also increases the risk of premature death after diagnosis of heart failure [3, 4]. Furthermore, heart failure is the second most common initial presentation of cardiovascular disease in people with type 2 diabetes and more common than myocardial infarction or stroke [5]. Although heart failure appears to be a complication of diabetes [6], this is still not fully recognised [1]. The number of people with heart failure is expected to increase continuously in the future, and thus efficient earlier prevention and treatment of heart failure is crucial.
Accumulating evidence has found that there are considerable sex differences in the excess risk of cardiovascular diseases associated with diabetes [7]. Our previous meta-analyses have shown that, compared with men, women have a significantly greater excess risk of CHD [8], stroke [9], as well as the non-cardiovascular complications of dementia [10], and cancer [11], following diabetes. However, whether these associations are also observed for heart failure is unknown, as the previous meta-analysis on the diabetes–heart failure association [2] included single-sex studies, which may have led to unreliable results due to differences in methodology, confounding factors included and background risk between the studies of women alone and men alone. Herein, we report the most comprehensive systematic review of the literature with a meta-analysis of possible sex differences in the excess risk of heart failure consequent to diabetes using only studies that included both sexes.

Methods

Search strategy and selection criteria
We conducted a systematic search in PubMed on 16 November 2018 using a combination of text words and medical subject headings (electronic supplementary material [ESM] Table 1). The reference lists of identified studies were also reviewed to identify other relevant studies.
Observational cohort studies were included if they had provided sex-specific RRs, or equivalents, for the association between diabetes and heart failure in both women and men. Studies were excluded if they were cohorts based on individuals with any underlying diseases, reported data for a single sex only, did not adjust at least for age, or did not provide information about the variability around the point estimate. In cases of duplicate reports from the same study, the study providing the longest follow-up or the highest number of events was included. Two authors (T. Ohkuma and Y. Komorita) conducted the search and extracted the data independently, and uncertainties regarding the inclusion of studies and data extraction were discussed and resolved by mutual consent. The meta-analysis was conducted in accordance with Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines [12].
Data extraction and statistical analysis
The primary outcome was incident heart failure (either fatal or non-fatal). The primary metrics were the pooled multiple-adjusted sex-specific RRs and the women-to-men ratio of RRs (RRRs) for heart failure, comparing individuals with diabetes with those without diabetes. In pooling multiple-adjusted RRs, the set of adjustments made was allowed to vary by study, but had to include at least one other risk factor for heart failure, in addition to age. Multiple RRs of subgroups from one study were combined into a single RR using a fixed-effect model. The pooled estimates of sex-specific RRs across studies were computed using random-effects meta-analyses with inverse variance weighting applied on the log scale. The same method was used to pool the RRRs. Data on type 1 and type 2 were separately pooled, where studies which did not differentiate type of diabetes were classified as type 2, which accounts for about 90–95% of all individuals with diabetes [13]. The I2 statistic was used to estimate the percentage of variability across studies due to between-study heterogeneity. Cochran’s Q test was used to assess whether there was a significant between-study heterogeneity.
Age-adjusted RRs were also pooled separately in secondary analyses. A sensitivity analysis was conducted to compare multiple-adjusted and age-adjusted estimates, where the studies were restricted to those that reported both. The presence of publication bias was examined using funnel plots and Egger’s and Begg’s tests. Meta-regression analyses tested for differences between prespecified subgroups in multiple-adjusted analyses: study region (Asia or non-Asia), year of baseline study (pre-1985 or 1986 onwards), ascertainment of diabetes (self-reported only or others), study outcome (fatal only or fatal and non-fatal combined), study quality (the Newcastle-Ottawa Scale [14] [ESM text and ESM Table 2], ≥8 or <8 points) and by absolute risk differences (greater in men or greater in women). Since only two studies were identified for type 1 diabetes, the analyses described in this paragraph were only applied for type 2 diabetes.
A p value <0.05 was considered to be statistically significant. All analyses were performed using Stata software (release 13; StataCorp, College Station, TX, USA).

Results

Of the 5991 articles identified by the systematic search, 760 articles qualified for full-text evaluation, and 14 articles provided summary data for sex differences in the association between diabetes and the risk of heart failure [5, 1527] (Fig. 1).
The characteristics of all 14 studies included are shown in Table 1 and ESM Table 2. Data on type 1 diabetes and heart failure were available from two studies, involving two cohorts, including 3,284,123 individuals, and 95,129 events. Data on type 2 diabetes and heart failure were available from 13 studies, involving 47 cohorts, including 11,925,128 individuals, and 249,560 events, among which two studies, involving two cohorts, including 368,072 individuals, and 4584 events, reported age-adjusted RRs only. Nine studies provided data on absolute risks (ESM Table 3).
Table 1
Characteristics of the studies reporting on the association between diabetes and heart failure
Cohort
Country
Baseline years
Follow-up (years)
Study population
N (% women)
Age range (years)
N of diabetes (% women)
Type of diabetes
Ascertainment of diabetes
N of outcome (% women)
Fatal or non-fatal
Maximum adjustment available
APCSC [16] a
Pool of 32 cohorts
1966–1999
7
Population-based, occupational settings
543,694 (36)
≥20
NA
Both
Self-reported, measured
496 (NA)
F
Age, SBP, BMI, cigarette smoking, regression dilution bias, study (stratified)
Policardo et al [23] b
Italy
2008
5
Population-based
3,192,203 (NA)
≥16
152,954 (NA)
Both
Prescription, exemption from paying for diabetes, hospitalisation with diagnosis of diabetes
26,154 (55)
Both
Age, CCI, previous hospitalisations for other CVD
KPMCP [26]
US
1978–1984
9.5 median
Health maintenance organisation
64,877 (54)
≥40
NA
Both
Self-reported, measured
1330 (46)
Both
Age, race, education, HT, MI, frequent chest pain, TC, BMI, creatinine, uric acid, urine protein, LVH, smoking, alcohol c
LRPP [25]
US, pool of 4 cohorts
1948, 1971, 1987–1989, 1967–1973
27.1, 20.3 (for index aged 45 and 55)
Population-based
19,249 (50), 23,915 (53) (for index aged 45 and 55)
30–62, 5–70, 45–64, ≥18
659 (46), 1792 (52) (for index aged 45 and 55)
Both
Measured, treatment
1677 (47), 2976 (52) (for index aged 45 and 55)
Both
Age, race, education, smoking status, HT, obesity
CHS [24]
US
1989–1990, 1992–1993
12.5 median
Population-based
4817 (61)
≥65
681 (53)
Both
Measured, treatment
1342 (57)
Both
Age, clinical site, education, smoking, alcohol consumption, BMI, physical activity
Swedish NDR (T1) [27]
Sweden
1998–2011
T1: 7.9, control: 8.3
Population-based (T1 was identified through NDR)
T1: 33,402 (45), control: 166,228 (45)
≥18
33,402 (45)
T1
NDR
2387 (39)
Both
Age, time-updated diabetes duration, birth in Sweden, educational level, baseline comorbidities
Swedish NDR (T2) [20]
Sweden
1998–2012
5.6 median
Population-based (T2 was identified through NDR)
T2: 266,305 (45), control: 1,323,504 (45)
T2: 62, control: 62 mean
266,305 (45)
T2
NDR
T2: 18,715 (46), control: 50,157 (45)
Both
Age, duration of diabetes, income, education, marital status, immigration status, stroke, acute MI, CHD, AF, renal dialysis or transplantation
Kaiser Permanente Georgia [17]
US
2000–2005
2.8
Health maintenance organisation
359,947 (53)
≥18
12,344 (49)
Both
Medical record, pharmacy claim
4001 (50)
Both
Age, HT, coronary artery disease, AF, valvular heart disease
NHANES I Epidemiologic Follow-up Study [15]
US
1971–1975
19
Population-based
13,643 (59)
25–74
521 (61)
Both
Self-reported
1382 (46)
Both
Age, race, education, physical activity, smoking, alcohol consumption, overweight, HT, valvular heart disease, CHD, BMI, SBP, TC, hypercholesterolaemia
Taiwan’s NHI system [19]
Taiwan
2000
T2: 7.8, control: 8.0
Population-based
T2: 34,291 (47), control: 34,291 (47)
60 mean
34,291 (47)
T2
Ambulatory care claims
8420 (51)
Both
Age, geographical area, urbanisation status, Hx of CHD, Hx of coronary revascularisation procedures, statins, β-blockers, diuretics
Saskatchewan Health databases [22]
Canada
1991–1996
5.2
Population-based
T2 11,881 (45), control: 552,765 (51)
≥30
11,881 (45)
T2
Prescription
2263 (46)
Both
Age
CALIBER programme [5]
UK
1998–2010
5.5 median
Primary care practices
1,921,260 (51)
≥30
34,198 (46)
T2
Medical record
13,938 (NA)
Both
Age, BMI, deprivation, HDL-C, TC, SBP, smoking, statin and antihypertensive drug prescriptions
Ballotari et al [21]
Italy
2011
3
Population-based
356,191 (51)
30–84
24,348 (44)
T2
Diabetes register
2321 (44)
Both
Age, foreign status d
NHS Information Services Scotland [18]
UK
2004–2013
10
Population-based
T1: 18,240 (45), T2 136,042 (46), no diabetes 3,066,253 (54)
≥30
T1: 18,240 (45), T2: 136,042 (46)
T1, T2
Diabetes register
T1: 1313 (NA), T2: 22,959 (NA), no diabetes: 91,429 (NA)
Both
Age, socioeconomic status, calendar year e
If endpoints were reported as incident, they were considered to include both fatal and non-fatal events, e.g. hospitalisation for heart failure
aN of total participants in APCSC was derived from overall participants. One out of 36 cohorts in APCSC (n = 12,203/543,694, 2.2%) consisted of male only
bN of total participants in Policardo et al was derived from overall participants (≥16 years old)
cRRs for controlled diabetes in participants aged <60 were extracted
dRRs were classified to be age-adjusted
eRRs for 2013 (aged ≥30 years) were extracted
AF, atrial fibrillation; APCSC, Asia Pacific Cohort Studies Collaboration; CALIBER, Cardiovascular disease research using LInked Bespoke studies and Electronic health Records; CCI, Charlson Comorbidity Index; CHS, Cardiovascular Health Study; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; F, fatal; HDL-C, HDL-cholesterol; HT, hypertension; Hx, history; KPMCP, Northern California Kaiser Permanente Medical Care Program; LRPP, Cardiovascular Disease Lifetime Risk Pooling Project (Framingham Heart, Framingham Offspring, Atherosclerosis Risk In Communities [ARIC], Chicago Heart Association Detection Project in Industry Study [CHA]); LVH, left ventricular hypertrophy; MI, myocardial infarction; NA, not available; NDR, National Diabetes Registry; NHANES I, First National Health and Nutrition Examination Survey; NHI, National Health Insurance; NHS, National Health Service; SBP, systolic BP; T1, type 1 diabetes; T2, type 2 diabetes; TC, total cholesterol
The multiple-adjusted pooled sex-specific RRs for heart failure associated with type 1 diabetes were 5.15 (95% CI 3.43, 7.74, p < 0.001) in women and 3.47 (2.57, 4.69, p < 0.001) in men (Fig. 2). The pooled multiple-adjusted RRR indicated a significantly greater excess risk for heart failure in women with type 1 diabetes compared with men. The women-to-men RRR was 1.47 (1.14, 1.90, p = 0.003 [Fig. 3]). The I2 statistics for heterogeneity between studies were 0.0%.
The sex-specific RRs for heart failure associated with type 2 diabetes was 1.95 (95% CI 1.70, 2.22, p < 0.001) in women and 1.74 (1.55, 1.95, p < 0.001) in men (Fig. 2), with the women-to-men RRR of 1.09 (1.05, 1.13), p < 0.001, I2 = 0.0% (Fig. 3). There was no evidence of publication bias for the association between type 2 diabetes and heart failure (Egger’s test p = 0.27, Begg’s test p = 0.31, ESM Fig. 1). In subgroup analyses, the pooled women-to-men multiple-adjusted RRR did not differ significantly by study region (p = 0.29), year of baseline study (p = 0.87), ascertainment of diabetes (p = 0.72), study outcome (p = 0.41), quality of study (p = 0.25), or absolute risk differences between men and women (p = 0.16) (Fig. 4).
For type 2 diabetes, five studies provided age-adjusted estimates. The pooled age-adjusted sex-specific RRs for heart failure associated with diabetes were 2.56 (95% CI 2.31, 2.84, p < 0.001) in women and 2.49 (2.04, 3.04, p < 0.001) in men. The pooled age-adjusted women-to-men RRR for heart failure was 1.00 (0.78, 1.27, p = 0.98). The I2 statistics for heterogeneity between studies was 87.6%, suggesting substantial heterogeneity.
In sensitivity analysis, restricted to studies which provided the sex-specific RRs for both multiple-adjusted and age-adjusted models, the pooled women-to-men RRR was 1.17 (95% CI 1.02, 1.35, p = 0.02) for multiple-adjusted analysis, and 1.19 (1.06, 1.34, p = 0.005) for age-adjusted analysis (ESM Fig. 2).

Discussion

The present meta-analysis, of 47 cohorts including more than 12 million individuals, showed that both type 1 and type 2 diabetes were a stronger risk factor for heart failure in women than men. Type 1 diabetes was associated with a 47% greater excess risk of heart failure in women compared with men, and type 2 diabetes was associated with a 9% greater excess risk of heart failure in women than men. The sex difference in the association between type 2 diabetes and heart failure was consistent across a range of prespecified subgroups. These findings are in agreement with the previous evidence showing that diabetes has stronger associations with diabetic complications for women than men, and shed light on the importance of a routine sex-specific approach both in research and clinical practice in this field.
A previous meta-analysis reported that diabetes was associated with the risk of heart failure in both women and men [2]. However, this previous meta-analysis included studies consisting of women or men only, as well as studies among both women and men, and therefore could have introduced bias in quantifying sex differences. Further, sex-specific RRs were not reported for type 1 diabetes. The present meta-analysis includes additional two-sex studies that were not included previously, and provides evidence that both type 2 diabetes and type 1 diabetes are a risk factor for heart failure in both sexes, with significantly stronger associations in women than men. These findings suggest that healthcare providers and policy makers should be aware of this greater excess risk of heart failure, as well as other diabetic complications [811, 28, 29], in women than men.
In our analyses of type 2 diabetes, the women-to-men RRR was greater when multiple-adjusted RRs were pooled compared with when age-adjusted RRs were pooled (multiple-adjusted RRR 1.09 [95% CI 1.05, 1.13] vs age-adjusted RRR 1.00 [0.78, 1.27]). A significant degree of heterogeneity between studies was observed for age-adjusted analyses (I2 = 87.6%, p < 0.001), but not for multiple-adjusted analyses (I2 = 0.0%, p = 0.834). On the other hand, the sensitivity analysis including the studies that reported both multiple-adjusted and age-adjusted estimates provided almost similar results, indicating a greater excess risk of heart failure associated with diabetes in women than men. Therefore, we speculate that the difference observed between multiple-adjusted and age-adjusted analyses is likely due to chance differences between the studies included. Furthermore, we believe that multiple-adjusted estimates, which adjust for other major cardiovascular risk factors in addition to age, are more likely to represent true aetiology.
There are several potential explanations for the greater excess risk of heart failure associated with diabetes in women compared with men. First, the observed sex differences could be driven by there being a greater risk of CHD conferred by diabetes in women than men, because CHD is a major cause of heart failure in people with type 2 diabetes [1]. Our previous large-scale meta-analyses showed that diabetes conferred a 44% greater excess risk of incident CHD in women than men [8]. A significant sex difference was also observed in a meta-analysis which focused specifically on type 1 diabetes and CHD [28]. Sex differences in the management of diabetes could underpin these associations. Historically, women with diabetes had poorer glycaemic control than men with diabetes [3034]. Second, in addition to CHD, undertreatment for women with diabetes could also contribute to the development of diabetic cardiomyopathy, a form of cardiac dysfunction that occurs independently of CHD and hypertension [35, 36], and could subsequently lead to a stronger association of diabetes with heart failure in women than men. Third, prolonged exposure to hyperglycaemia during the prediabetic state may also be involved. Women were reported to have 2 years longer duration of prediabetes than men [37]. Longer duration of prediabetes has been shown to be associated with left ventricular systolic and diastolic dysfunction [38]. Finally, it is also possible that sex differences in other cardiovascular risk factor profiles [3033, 3941] account for the greater excess risk of heart failure associated with diabetes in women compared with men. Deteriorations in major cardiovascular risk factor levels in individuals with diabetes compared with those without diabetes are reported to be greater in women than in men [9, 42, 43].
It might be also possible that the sex differences found in this study are a mathematical artefact caused by the relatively low absolute risk for heart failure in women compared with men. Suppose that the absolute risk difference following diabetes is the same in men as it is in women, then there would automatically be a larger RR among women compared with men. However, RRs, rather than absolute risk differences, are much more commonly reported in clinical studies, given their stability across different populations. No sex differences between women and men were found in our previous meta-analyses for risk factors and cardiovascular diseases [44, 45], which indicates that detection of a female disadvantage based on RRs is not inevitable.
Regarding type of diabetes, the excess risk of heart failure associated with diabetes was greater in type 1 diabetes than type 2 diabetes. The women-to-men RRR was 1.47 (95% CI 1.14, 1.90) for type 1 diabetes, and 1.09 (1.05, 1.13) for type 2 diabetes. The reason for this difference between type 1 and type 2 diabetes is unclear, but it may be partly explained by the above-mentioned sex differences in the association between diabetes and CHD. In our previous meta-analyses, type 1 diabetes showed a stronger sex difference in the association with incident CHD than type 2 diabetes, with women-to-men RRR of 2.54 (1.80, 3.60) for type 1 diabetes [28] and 1.44 (1.27, 1.63) for type 2 diabetes [8]. Future large-scale individual participant data meta-analysis and mechanistic studies might elucidate this difference.
The strengths of this meta-analysis are the large number of study participants and exclusion of studies which provided data for only one sex, which reduced the risk of both sampling and non-sampling error. This enabled us to provide robust evidence on the presence of sex differences in the risk of heart failure conferred by diabetes. Furthermore, the findings were consistent across a range of prespecified subgroups. Some limitations of this study should be mentioned. First, this meta-analysis was based on published data, with heterogeneity in study design, ascertainment of diabetes, definition of endpoint and extent of adjustment for confounding factors across studies. However, since we only included studies with results for both sexes, we minimised these issues by conducting within-study comparisons of the sexes. Second, there may be other unmeasured confounding factors in addition to those adjusted for in each study. Third, information on duration of diabetes, glycaemic control, glucose-lowering drugs or phenotype of heart failure was not available, and thus we cannot conduct detailed assessments regarding these factors. Analyses considering these factors would provide insight into potential explanation for the observed sex differences, and will be the subject of our future research. Fourth, the competing risk of premature death was not adjusted for in the present meta-analysis. Men with diabetes are at an increased risk of premature death compared with women with diabetes [46] (as indeed is the case in general populations), and therefore may be less likely to develop heart failure. This could partly explain the greater excess risk of heart failure following diagnosis of diabetes in women than men. Finally, we only found two studies of type 1 diabetes, which compromises the accuracy of our estimates in this regard. Additional studies are needed to address this issue.
In conclusion, the excess risk of heart failure following diagnosis of diabetes is significantly greater in women than men, highlighting the importance of intensive prevention and treatment of diabetes for women as well as men. Further research is required to understand the mechanisms underpinning the excess risk of heart failure conferred by diabetes (particularly type 1) in women and to reduce the burden associated with diabetes in both sexes.

Duality of interest

MW is a consultant to Amgen and Kirin. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

e.Med Allgemeinmedizin

Kombi-Abonnement

Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.

Anhänge

Electronic supplementary material

Literatur
3.
Zurück zum Zitat Dauriz M, Targher G, Laroche C et al (2017) Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA heart failure long-term registry. Diabetes Care 40(5):671–678. https://doi.org/10.2337/dc16-2016 CrossRefPubMed Dauriz M, Targher G, Laroche C et al (2017) Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA heart failure long-term registry. Diabetes Care 40(5):671–678. https://​doi.​org/​10.​2337/​dc16-2016 CrossRefPubMed
4.
Zurück zum Zitat Johansson I, Edner M, Dahlstrom U, Nasman P, Ryden L, Norhammar A (2014) Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management? An observational study from the Swedish Heart Failure Registry. Eur J Heart Fail 16(4):409–418. https://doi.org/10.1002/ejhf.44 CrossRefPubMed Johansson I, Edner M, Dahlstrom U, Nasman P, Ryden L, Norhammar A (2014) Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management? An observational study from the Swedish Heart Failure Registry. Eur J Heart Fail 16(4):409–418. https://​doi.​org/​10.​1002/​ejhf.​44 CrossRefPubMed
10.
13.
Zurück zum Zitat American Diabetes Association (2019) Standards of medical care in diabetes-2019. Diabetes Care 42:S1–S186CrossRef American Diabetes Association (2019) Standards of medical care in diabetes-2019. Diabetes Care 42:S1–S186CrossRef
21.
Zurück zum Zitat Ballotari P, Venturelli F, Greci M, Giorgi Rossi P, Manicardi V (2017) Sex differences in the effect of type 2 diabetes on major cardiovascular diseases: results from a population-based study in Italy. Int J Endocrinol 2017:6039356CrossRefPubMedPubMedCentral Ballotari P, Venturelli F, Greci M, Giorgi Rossi P, Manicardi V (2017) Sex differences in the effect of type 2 diabetes on major cardiovascular diseases: results from a population-based study in Italy. Int J Endocrinol 2017:6039356CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Ryden L, Grant PJ, Anker SD et al (2013) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34(39):3035–3087. https://doi.org/10.1093/eurheartj/eht108 CrossRefPubMed Ryden L, Grant PJ, Anker SD et al (2013) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34(39):3035–3087. https://​doi.​org/​10.​1093/​eurheartj/​eht108 CrossRefPubMed
42.
Metadaten
Titel
Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals
verfasst von
Toshiaki Ohkuma
Yuji Komorita
Sanne A. E. Peters
Mark Woodward
Publikationsdatum
18.07.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 9/2019
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-019-4926-x

Weitere Artikel der Ausgabe 9/2019

Diabetologia 9/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.